ReviewFrontiers in microbiology2021
Nanostructured Antimicrobial Peptides: Crucial Steps of Overcoming the Bottleneck for Clinics.
Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Peptide-Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives.ChemMedChem · 2026Review
- Targeting Bacterial Infections in Periodontal Disease: From Conventional Antibiotics to Next-Generation Therapeutics.Antibiotics (Basel, Switzerland) · 2026Review
- Artificial Intelligence-Driven Discovery and Optimization of Antimicrobial Peptides Targeting ESKAPE Pathogens and Multidrug-Resistant Fungi.Microorganisms · 2026Review
- Synergy between Antimicrobial Peptides and Lipid Nanoparticles for Skin Infection Control.ACS applied materials & interfaces · 2026Review
- Self-assembled nanonetworks of highly stable gemini surfactant-like peptides: antibacterial mechanisms, self-assembly characteristics, and in vivo anti-infection potential.Journal of nanobiotechnology · 2026Article
- The interactions between antimicrobial materials and bacterial membranes.Frontiers in chemistry · 2026Review
- Nanomedicine against antimicrobial resistance: mechanistic insights and next-generation therapeutic potential.Frontiers in chemistry · 2026Review
- Design of Peptide-Modified Aluminum Nanoparticles with Enhanced Antimicrobial, Antibiofilm, Antioxidant, and DNA-Cleaving Properties.Pharmaceutics · 2025Article
- Assessing the Mechanism of Action of Synthetic Nanoengineered Antimicrobial Polymers against the Bacterial Membrane ofBiomacromolecules · 2025Article
- Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures.Folia microbiologica · 2025Review
- Current Status of the Application of Antimicrobial Peptides and Their Conjugated Derivatives.Molecules (Basel, Switzerland) · 2025Review
- Potential Compounds as Inhibitors of Staphylococcal Virulence Factors Involved in the Development of Thrombosis.Toxins · 2025Review
- Pneumolysin-responsive liposomal platform for selective treatment of Streptococcus pneumoniae.Drug delivery and translational research · 2025Article
- Plant Defense Peptides: Exploring the Structure-Function Correlation for Potential Applications in Drug Design and Therapeutics.ACS omega · 2025Review
- Advantages and Challenges of Using Antimicrobial Peptides in Synergism with Antibiotics for Treating Multidrug-Resistant Bacteria.ACS infectious diseases · 2025Review
- Photodynamic and photothermal bacteria targeting nanosystems for synergistically combating bacteria and biofilms.Journal of nanobiotechnology · 2025Article
- Conjugated therapeutic proteins as a treatment for bacteria which trigger cancer development.iScience · 2024Review
- Engineered extracellular vesicles coated with an antimicrobial peptide for advanced control of bacterial sepsis.Journal of extracellular biology · 2024Article
- Stable peptide-assembled nanozyme mimicking dual antifungal actions.Nature communications · 2024Article
- Eradication of Klebsiella pneumoniae pulmonary infection by silver oxytetracycline nano-structure.AMB Express · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The security issue of human health is faced with dispiriting threats from multidrug-resistant bacteria infections induced by the abuse and misuse of antibiotics. Over decades, the antimicrobial peptides (AMPs) hold great promise as a viable alternative to treatment with antibiotics due to their peculiar antimicrobial mechanisms of action, broad-spectrum antimicrobial activity, lower drug residue, and ease of synthesis and modification. However, they universally express a series of disadvantages that hinder their potential application in the biomedical field (e.g., low bioavailability, poor protease resistance, and high cytotoxicity) and extremely waste the abundant resources of AMP database discovered over the decades. For all these reasons, the nanostructured antimicrobial peptides (Ns-AMPs), based on a variety of nanosystem modification, have made up for the deficiencies and pushed the development of novel AMP-based antimicrobial therapies. In this review, we provide an overview of the advantages of Ns-AMPs in improving therapeutic efficacy and biological stability, reducing side effects, and gaining the effect of organic targeting and drug controlled release. Then the different material categories of Ns-AMPs are described, including inorganic material nanosystems containing AMPs, organic material nanosystems containing AMPs, and self-assembled AMPs. Additionally, this review focuses on the Ns-AMPs for the effect of biological activities, with emphasis on antimicrobial activity, biosecurity, and biological stability. The "state-of-the-art" antimicrobial modes of Ns-AMPs, including controlled release of AMPs under a specific environment or intrinsic antimicrobial properties of Ns-AMPs, are also explicated. Finally, the perspectives and conclusions of the current research in this field are also summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.